At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
- A Phase 1 Study of BBO-10203 in People With Advanced Solid Tumors
Full Title A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors
Purpose
Researchers want to find the best dose of BBO-10203 to use in people with advanced solid tumors. The people in this study have one of these types of cancer that has spread (metastasized):
- Breast cancer that makes an excess amount of the HER2 protein.
- Breast cancer that is negative for HER2 but is fueled by estrogen and/or progesterone.
- Non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS gene.
- Colorectal cancer with a KRAS mutation.
BBO-10203 may slow or stop cancer growth by blocking the interaction between two proteins. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the cancers listed above that continues to grow despite treatment.
- Have recovered from the serious side effects of prior therapies before taking BBO-10203.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-4226.
Protocol
25-038Phase
Phase I (phase 1)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06625775ClinicalTrials.gov
-
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
-
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
-
The purpose of this study is to find out how cancer treatments (chemotherapy and/or radiation therapy) affect reproductive and sexual health in people with early-onset colorectal cancer (diagnosed before age 50). Researchers will observe and track changes in hormone levels and in sexual and reproductive health in the study participants. This information will help them learn more about how cancer treatments affect reproductive and sexual health, including the ability to have children (fertility).
-
Researchers want to find the best dose of LY3962673 that can be used safely in people with advanced solid tumors. The people in this study have tumors that have metastasized (spread) or are inoperable (cannot be taken out with surgery). They include people with colorectal cancer, non-small cell lung cancer, and pancreatic cancer.
-
When some cancers become advanced, particularly colorectal cancer, they may spread to the liver. Destroying the tissue with electromagnetic waves that produce extremely high temperatures, a procedure called "thermal ablation," is one way to treat these liver metastases.
-
This study is comparing the effectiveness of combination chemotherapy plus tucatinib and trastuzumab versus combination chemotherapy alone in people with metastatic colorectal cancer that is positive for the HER2 protein. The combination chemotherapy is called mFOLFOX6 (oxaliplatin, leucovorin or levoleucovorin, and fluorouracil) and it is a standard treatment for advanced colorectal cancer.
-
Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).
-
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
-
The purpose of this study is to find the highest dose of the investigational drug RMC-6236 that can be given safely in people with advanced solid tumors containing mutations in the KRAS gene. RMC-6236 targets the KRAS protein made by the mutated gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of cancer cells. RMC-6236 is taken orally (by mouth).